Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
Amgen has announced a total revenue of $8.5bn in Q3 2024, a 23% increase from a $6.9bn revenue in the…
All articles by Justine Ra
Justine Ra
Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.
-
-
LEO’s Adbry demonstrates long-term efficacy in atopic dermatitis
LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s…
-
Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic
Thermo Fisher Scientific has announced that its in vitro diagnostic test, Oncomine, has won US Food and Drug Administration (FDA)…
-
Sage lays off 55% of R&D workforce and refocuses pipeline
After a series of mid-stage clinical trial failures, Sage Therapeutics has announced that it will jettison 165 employees, which totals…
-
South Korean company Dong-A ST wins FDA approval for Stelara biosimilar
South Korea-based Dong-A ST has received a US Food and Drug Administration (FDA) approval for Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar that…
-
Neuvivo makes bid to enter ALS arena with immunotherapy candidate
Neuvivo has submitted a New Drug Application (NDA) for its investigational amyotrophic lateral sclerosis (ALS) immunotherapy to the US Food…
-
Triveni scores $115m to expand immunology pipeline
Triveni Bio has secured $115m in a Series B funding round to advance its preclinical antibody candidates for immunological and…
-
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US…
-
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms…
-
Japan approves updated Covid-19 vaccine to tackle JN.1 variant
CSL and Arcturus Therapeutics’s self-amplifying mRNA (sa-mRNA) vaccine, Kostaive (ARCT-154) has been approved in Japan to tackle the JN.1 strain…